PO.BCS02.06 · 生物信息与计算

ProteoBridge: Bridging skipped sections via histology-based protein prediction

海报缩略图:ProteoBridge: Bridging skipped sections via histology-based protein prediction
编号 4218 展板 14 时间 4/21 09:00–12:00 区域 Section 5 主讲 Minji Kim, MS
分会场 Machine Learning Approaches for Cancer Prediction
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Minji Kim1, Sunho Park2, Seock-Jin Chung1, Inyeop Jang1, Jean R. Clemenceau1, Soyoung Im3, Eric Sha1, Hwanil Choi4, Soonyoung Lee4, Jongseong Jang4, Sam C. Wang5, Tae Hyun Hwang1

1Section Surgical Research, Vanderbilt University Medical Center, Nashville, TN,2Surgical Section Research, Vanderbilt University Medical Center, Nashville, TN,3College of medicine, The Catholic University, Suwon, Korea, Republic of,4LG AI Research, Seoul, Korea, Republic of,5University of Texas Southwestern Medical Center, Dallas, TX

摘要 Abstract

Background: The progress of spatial multimodal platforms has enabled high-resolution mapping of various types of molecular and morphological characteristics within a tissue. Proteins influence cellular phenotypes and the organization of the tumor microenvironment, with their abundance and patterns highly correlated in adjacent serial sections. Spatial Multimodal platforms such as Singular Genomics G4X, which capture H&E-stained images, multiplexed protein expression, and targeted RNA transcriptomics from the same tissue slide, now create a foundation for three-dimensional (3D) spatial multimodal profiling and 3D tumor microenvironment modeling. However, comprehensive multiplex protein imaging across entire tissue stacks is costly, labor-intensive, and impractical, leading to sparse proteomic sampling that limits accurate 3D reconstruction.Methods: We developed ProteoBridge, a deep learning-based framework that predicts protein expression patterns across serial tissue sections to densify the proteomic information needed for 3D molecular modeling. For each tissue stack, the model was trained on the first section, which contains H&E, multiplex protein images, and RNA transcriptomics. The inputs include H&E tiles and RNA transcriptome data, while the outputs are multi-channel protein maps for the same field of view. The combination of targeted RNA transcriptomics and H&E stained morphology helps define cell types and states, allowing the model to learn morphology-to-protein relationships based on transcriptional programs. The training focused on reducing mean absolute error across protein channels to establish histology-protein correspondences for unmeasured sections.Results: We evaluated ProteoBridge on tissue stacks with multiple profiled sections. Image-level similarity between predicted and measured protein maps was assessed. Using single-slide supervision, ProteoBridge accurately reproduced marker intensities and preserved cross-plane consistency, capturing both intensity values and spatial organization of proteins.. By filling in skipped planes, ProteoBridge generates a more continuous 3D representation of the tumor proteome suitable for downstream 3D molecular modeling and visualization.Conclusion: ProteoBridge requires only routine H&E staining on the remaining sections in a stack to infer protein intensities across serial planes, reducing cost and turnaround time while expanding effective proteomic coverage. Using the G4X platform's multimodal data and extending protein predictions to unmeasured areas allows for cost-effective 3D reconstruction of the tumor proteome, enhancing molecular modeling of the tumor microenvironment and its heterogeneity.Generative AI assisted only with language editing of this abstract. The authors retain sole responsibility for the scientific content and conclusions, having reviewed and approved the final version.
利益披露 Disclosure
M. Kim, None.. S. Park, None.. S. Chung, None.. I. Jang, None.. J. R. Clemenceau, None.. S. Im, None.. E. Sha, None. H. Choi, LG AI Research Employment. S. Lee, LG AI Research Employment. J. Jang, LG AI Research Employment. S. C. Wang, None. T. Hwang, Kure.ai therapeutics Other Business Ownership, T.H.H. is a co-founder of Kure.ai therapeutics. Kure.s Other Business Ownership, T.H.H. is a co-founder of Kure.s. IQVIA Other, T.H.H. has received consulting fees from IQVIA.

在会议检索中打开